A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Obeticholic Acid In Subjects With Nonalcoholic Steatohepatitis.
Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Active
The study is event driven and total duration will be determined by the time required to accrue approximately 264 adjudicated events for the clinical outcomes composite endpoint, in the OCA 25 mg and placebo groups combined, for subjects with fibrosis stage 2 and stage 3, estimated to take approximately up to 6 years.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.